Volume 10 Number 2 2026
Computational Design of Protein-Based Diagnostic Assays for Early Cancer Detection: Platforms, Algorithms, and the Road to Clinical Translation
Khaldoon Mustansir 1*
Integrative Biomedical Research 10 (2) 1-8 https://doi.org/10.25163/biomedical.10210970
Submitted: 18 August 2026 Revised: 08 October 2026 Accepted: 14 October 2026 Published: 16 October 2026
Most cancers are still found late, when cure is the exception rather than the rule. Imaging-based screening and single serum markers such as PSA, CA 125, and CEA have helped, but their false-positive rates and weak sensitivity for localized disease leave a wide gap, and blood-based protein profiling offers one plausible way to narrow it. This review examines how computational design is reshaping protein diagnostics, from discovery to the regulatory desk. We describe the analytical platforms used to interrogate the circulating proteome, including data-dependent and data-independent mass spectrometry, proximity extension assays, aptamer arrays, functional protein microarrays, and extracellular vesicle isolation systems, weighing their sensitivity, dynamic range, and throughput against a plasma proteome that spans twelve or more orders of magnitude. We then follow the algorithmic chain that turns thousands of noisy measurements into a compact, locked decision rule: penalized regression, recursive feature elimination, ensemble and neural classifiers, decision fusion, explainable artificial intelligence, and resampling-based validation. Representative panels are synthesized for multi-cancer early detection and for lung, colorectal, esophageal, and liver cancers; several report areas under the curve above 0.95 and encouraging stage I sensitivity, although most derive from case–control designs that probably flatter real-world performance. Finally, we consider what tends to stall translation: pre-analytical variability, high-abundance protein masking, overfitting, incomplete TRIPOD and REMARK reporting, and the demands of FDA 510(k), De Novo, and premarket approval pathways. Computationally designed multi-protein panels look promising, but their clinical value will depend on prospective, population-based validation rather than further gains in retrospective accuracy.
Keywords: early cancer detection; liquid biopsy; plasma proteomics; multi-protein biomarker panel; machine learning; proximity extension assay; mass spectrometry; extracellular vesicles; multi-cancer early detection; regulatory science.
Barabási, A.-L., Gulbahce, N., & Loscalzo, J. (2011). Network medicine: A network-based approach to human disease. Nature Reviews Genetics, 12(1), 56–68.
Benito-León, J., Gómez-Isla, T., & Hernández-Gallego, J. (2021). Using unsupervised machine learning to identify age- and sex-independent severity subgroups among patients with COVID-19: Observational longitudinal study. Journal of Medical Internet Research, 23(5), e25988.
Conte, F., Fiscon, G., Licursi, V., Bizzarri, D., D’Antò, T., Farina, L., & Paci, P. (2020). A paradigm shift in medicine: A comprehensive review of network-based approaches. Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms, 1863(6), 194416.
Coste, J., Delpierre, C., Robineau, O., Rushyizekera, M., Richard, J.-B., Alleaume, C., Gallay, A., Tebeka, S., Steichen, O., Lemogne, C., & Makovski, T. T. (2025). A multidimensional network of factors associated with long COVID in the French population. Communications Medicine, 5, 846.
Fiscon, G., Conte, F., Farina, L., & Paci, P. (2021). SAveRUNNER: A network-based algorithm for drug repurposing and its application to COVID-19. PLOS Computational Biology, 17(2), e1008686.
Gordon, D. E., Jang, G. M., Bouhaddou, M., Xu, J., Obernier, K., White, K. M., O’Meara, M. J., Rezelj, V. V., Guo, J. Z., Swaney, D. L., Tummino, T. A., Huettenhain, R., Kaake, R. M., Richards, A. L., Tutuncuoglu, B., Foussard, H., Batra, J., Haas, K. M., Modak, M., ... Krogan, N. J. (2020). A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature, 583(7816), 459–468.
Halamka, J., Cerrato, P., & Perlman, A. (2020). Redesigning COVID-19 care with network medicine and machine learning. Mayo Clinic Proceedings: Innovations, Quality & Outcomes, 4(6), 762–769.
Hsieh, K., Wang, Y., Chen, L., Zhao, Z., Savitz, S., Jiang, X., Tang, J., & Kim, Y. (2021). Drug repurposing for COVID-19 using graph neural network and harmonizing multiple evidence. Scientific Reports, 11, 2353.
Ilbeigipour, S., Albadvi, A., & Noughabi, E. A. (2022). Cluster-based analysis of COVID-19 cases using self-organizing map neural network and K-means methods to improve medical decision-making. Informatics in Medicine Unlocked, 32, 101005.
Jamshidi, M. B., Lalbakhsh, A., Talla, J., Peroutka, Z., Hadj-Alouane, F., Roshani, S., ... & Sprogis, A. (2020). Artificial intelligence and COVID-19: Deep learning approaches for diagnosis and treatment. IEEE Access, 8, 109581–109591.
Koss, C., & Bohnet-Joschko, S. (2022). Generating hypotheses on drug repurposing from discussions among long-haulers on Reddit: Social media mining study. JMIR Formative Research, 6(10), e39582.
Li, X., Yu, J., Zhang, Z., Ren, J., Peluffo, A. E., Zhang, W., Zhao, Y., Wu, J., Yan, K., Cohen, D., & Wang, W. (2021). Network bioinformatics approach helps to predict 30 repurposable drugs against COVID-19. Medicine in Drug Discovery, 10, 100090.
Messina, F., Giombini, E., Agrati, C., Vairo, F., Ascoli Bartoli, T., Al Moghazi, S., Piacentini, M., Locatelli, F., Kobinger, G., Maeurer, M., Zumla, A., Capobianchi, M. R., Lauria, F. N., & Ippolito, G. (2020). COVID-19: Viral–host interactome analyzed by network based-approach model to study pathogenesis of SARS-CoV-2 infection. Journal of Translational Medicine, 18, 233.
Morselli Gysi, D., do Valle, Í., Zitnik, M., Ameli, A., Gan, X., Varol, O., Ghiassian, S. D., Patten, J. J., Davey, R. A., Loscalzo, J., & Barabási, A.-L. (2021). Network medicine framework for identifying drug-repurposing opportunities for COVID-19. Proceedings of the National Academy of Sciences, 118(19), e2025581118.
Pavel, A., del Giudice, G., Federico, A., Di Lieto, A., Kinaret, P. A. S., Serra, A., & Greco, D. (2021). Integrated network analysis reveals new genes suggesting COVID-19 chronic effects and treatment. Briefings in Bioinformatics, 22(2), 1430–1441.
Pfaff, E. R., Madlock-Brown, C., Baratta, J. M., Bhatia, A., Davis, H., Girvin, A., Hill, E., Kelly, E., Kostka, K., Loomba, J., McMurry, J. A., Wong, R., Bennett, T. D., Moffitt, R., Chute, C. G., & Haendel, M. (2023). Coding long COVID: Characterizing a new disease through an ICD-10 lens. BMC Medicine, 21(1), 58.
Sadegh, S., Skelton, J., Anastasi, E., Bernett, J., Blumenthal, D. B., Galindez, G., Salgado-Albarrán, M., Lazareva, O., Flanagan, K., Cockell, S., Nogales, C., Casas, A. I., Schmidt, H. H. H. W., Baumbach, J., Wipat, A., & Kacprowski, T. (2021). Network medicine for disease module identification and drug repurposing with the NeDRex platform. Nature Communications, 12, 6848.
Santos, S. S., Torres, M., Galeano, D., Sánchez, M. M., Cernuzzi, L., & Paccanaro, A. (2022). Machine learning and network medicine approaches for drug repositioning for COVID-19. Patterns, 3(1), 100396.
Stolfi, P., Manni, L., Soligo, M., Vergni, D., & Tieri, P. (2020). Designing a network proximity-based drug repurposing strategy for COVID-19. Frontiers in Cell and Developmental Biology, 8, 545089.
Sun, X., Jiang, J., Wang, Y., & Liu, S. (2020). On coronavirus disease 2019 (COVID-19) through a combination of data mining and network pharmacology analysis. European Journal of Integrative Medicine, 40, 101242.
Tomazou, M., Bourdakou, M. M., Minadakis, G., Zachariou, M., Oulas, A., Karatzas, E., Loizidou, E. M., Kakouri, A. C., Christodoulou, C. C., Savva, K., Zanti, M., Onisiforou, A., Afxenti, S., Richter, J., Christodoulou, C. G., Kyprianou, T., Kolios, G., Dietis, N., & Spyrou, G. M. (2021). Multi-omics data integration and network-based analysis drives a multiplex drug repurposing approach to a shortlist of candidate drugs against COVID-19. Briefings in Bioinformatics, 22(6), bbab114.
Verstraete, N., Jurman, G., Bertagnolli, G., Ghavasieh, A., Pancaldi, V., & De Domenico, M. (2020). CovMulNet19, integrating proteins, diseases, drugs, and symptoms: A network medicine approach to COVID-19. Network and Systems Medicine, 1(1), 181–191.
Zeraatkar, D., Ling, M., Kirsh, S., Jassal, T., Pitre, T., Chakraborty, S., Turner, T., Turkstra, L., McIntyre, R. S., Izcovich, A., Mbuagbaw, L., Agoritsas, T., Flottorp, S. A., Garner, P., Couban, R. J., & Busse, J. W. (2025). Interventions for the management of post-COVID-19 condition (long COVID): Protocol for a living systematic review and network meta-analysis. BMJ Open, 15(2), e086407.
Zhou, Y., Hou, Y., Shen, J., Huang, Y., Martin, W., & Cheng, F. (2020a). Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2. Cell Discovery, 6(1), 14.
Zhou, Y., Hou, Y., Shen, J., Mehra, R., Kallianpur, A., Culver, D. A., Gack, M. U., Farha, S., Zein, J., Comhair, S., Fiocchi, C., Stappenbeck, T., Chan, T., Eng, C., Jung, J. U., Jehi, L., Erzurum, S., & Cheng, F. (2020b). A network medicine approach to investigation and population-based validation of disease manifestations and drug repurposing for COVID-19. PLOS Biology, 18(11), e3000970.
Zhou, Y., Xu, J., Hou, Y., Leverenz, J. B., Kallianpur, A., Mehra, R., Liu, Y., Yu, H., Pieper, A. A., Jehi, L., & Cheng, F. (2021). Network medicine links SARS-CoV-2/COVID-19 infection to brain microvascular injury and neuroinflammation in dementia-like cognitive impairment. Alzheimer's Research & Therapy, 13(1), 110.
Network Medicine Approaches to Long COVID: Integrating Multi-Omic Data to Redefine Disease Taxonomy
AI-Driven Target Identification Reshapes Early-Stage Drug Discovery in Triple-Negative Breast Cancer